gms | German Medical Science

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Deutsche Gesellschaft für Infektiologie,
Deutsche AIDS-Gesellschaft,
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit,
Paul-Ehrlich-Gesellschaft für Chemotherapie

23.06. - 26.06.2010, Köln

Impact of timing HAART-initiation on immune status and clinical course in the cohort of the German Competence Network for HIV/AIDS

Einfluß des frühen versus späten Beginns der ART auf Krankheitsverlauf und Immunstatus bei HIV-Infektion – eine Analyse des HIV-Kompetenznetzes

Meeting Abstract

  • A. Plettenberg - Ifi-Institut für interdisziplinäre Medizin, Hamburg, Germany
  • N.H. Brockmeyer - Kompetenznetz HIV/AIDS, Bochum, Germany; Ruhr-Universität, Dermatologische Klinik, Bochum, Germany
  • B. Haastert - mediStatistica, Neuenrade, Germany
  • S. Dupke - Gemeinschaftspraxis Driesener Straße, Berlin, Germany
  • K. Schewe - ICH St. Georg, Infektionsepidemiologisches Centrum, Hamburg, Germany
  • M. Rausch - Gemeinschaftspraxis Fuggerstraße, Berlin, Germany
  • M. Hower - Klinikum Dortmund, Dortmund, Germany
  • G. Arendt - Universitätsklinikum Düsseldorf, Düsseldorf, Germany
  • K. Jansen - Kompetenznetz HIV/AIDS, Bochum, Germany
  • Competence Network for HIV/AIDS

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010). Köln, 23.-26.06.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP158

doi: 10.3205/10kit212, urn:nbn:de:0183-10kit2123

Veröffentlicht: 2. Juni 2010

© 2010 Plettenberg et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Background: HAART has dramatically reduced morbidity and mortality in HIV-infected patients (pts) but optimal time of therapy initiation is still unknown. Several studies investigating this issue showed inconsistent results. Our study investigated whether there is a clinical benefit as to treated patients by an earlier start of therapy at CD4 between 350-449c/µl, compared to the range of 250–349c/µl. An analysis was conducted on basis of the open, retrospective and prospective, multi-center and nationwide cohort of the Competence Network for HIV/AIDS.

Methods: For analysis, pts had to be observed at least 3 months before initiation of HAART. Medication had to start later than 1996, with at least three substances. At time of therapy start (to), pts had to have 250c/µl<CD4-cells<450c/µl, no prior AIDS defining conditions and CD4 cells never below 200c/µl. Afterwards, pts were stratified in groups by initial CD4 cells between 250–349c/µl (group 1) and 350-449c/µl (group 2). Primary outcomes death, AIDS and first drop of CD4 cell count/µl< 200 cells were evaluated as censored event times between to and the date of first event resp. last observation. Time dependent probabilities of event free intervals since start of HAART were estimated by Kaplan-Meier estimation, compared by Log-rank-tests. Cox-regression models were fitted, adjusted for time since infection.

Results: 825 pts met inclusion criteria. Group 1 consisted of 526 pts, group 2 of 296. Mean observation time in group 1 was 5.1 years/pt (2,683 years overall), in group 2 4.9 years/pt (1,450 y overall). In group 1, 0.64 deaths occurred per 100 pt years vs. 0.17 events in group 2. 1.28 AIDS events were developed per 100 pt years vs. 0,78 events in group 2. In group 1, 2.64 per 100 pts years dropped <200c/µl vs. 0.77 in group 2. Kaplan-Meier estimations showed significant differences as to developing deaths and CD4 drop<200c/µl (ten years probabilities for having no event as to death: group1 95%, group2: 99%, p=0.045; as to CD4 drop< 200c/µl: group1 80%, group2: 94%, p=0.0004), but no significant differences as to AIDS (group1 92%, group2: 90%, p=0.219). Hazard ratios (group 2 vs. 1) were (borderline) significant for death (0.149, p=0.0678) and CD4 drop< 200c/µl (0.302, p=0.001), but not for AIDS (0,634, p=0.2417).

Conclusions: Treated pts profited by start of therapy with CD4 cell count ≥350c/µl regarding death and CD4 drop<200c/µl. These results may be a hint to start therapy earlier.